CompARE: study protocol for a phase III randomised controlled platform trial comparing alternative regimens for escalating treatment of intermediate and high-risk oropharyngeal cancer

Search results

• Active

  CRUK/13/026 CompARE Collect: Prospective biological sample collection from patients with intermediate and high risk oropharyngeal cancer recruited to comPARE randomised controlled trial

  Batis, N., Nankivell, P., Spruce, R. & Mehanna, H.

  Cancer Research Uk

  1/08/17 → 31/07/24

  Project: Research

  • Oropharyngeal Neoplasms 100%
  • durvalumab 74%
  • Biological Marker 68%
  • Randomized Controlled Trials 50%
  • Biomarkers 49%

• CRUK/13/026: CompARE: Phase III randomised controlled trial Comparing Alternative Regimens for escalating treatment of intermediate and high-risk oropharyngeal cancer

  Gaunt, P., Billingham, L., Mehanna, H. & Bowden, S.

  Cancer Research Uk, ASTRA ZENECA UK LIMITED, CITY HOSPITAL NHS TRUST

  1/11/14 → 31/12/25

  Project: Research

  • Oropharyngeal Neoplasms 100%
  • durvalumab 74%
  • Biological Marker 68%
  • Randomized Controlled Trials 50%
  • Biomarkers 49%
• Finished

  Cancer Research UK Clinical Trials Unit, Birmingham - Adult Unit

  Bach, S., Bowden, S., Craddock, C., Rea, D., Kearns, P., Wheatley, K., Billingham, L. & Steven, N.

  Cancer Research Uk

  1/10/18 → 30/09/23

  Project: Research

  • MK-1775 100%
  • beta-hydroxyisovaleric acid 90%
  • cabazitaxel 85%
  • Randomized Controlled Trials 73%
  • Oropharyngeal Neoplasms 72%